MBX Biosciences, Inc. (MBX)
Nasdaq: MBX · Pharmaceutical Preparations · Carmel, IN · filing with the SEC since 2019
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 12, 2026 | Mar 17, 2025 | · |
| Research and development | 79,159 | 57,415 | 28,534 |
| General and administrative | 18,896 | 10,779 | 6,777 |
| Total operating expenses | 98,055 | 68,194 | 35,311 |
| Operating income | -98,055 | -68,194 | -35,311 |
| Income before income taxes | -87,000 | -61,900 | · |
| Income tax expense | 0 | 0 | 0 |
| Net income including non-controlling interests | -86,971 | -61,922 | -32,563 |
| Net income | -86,971 | -61,922 | -32,563 |
| Net income to common shareholders | -86,971 | -61,922 | -32,563 |
| Earnings per share, basic | -2.38 | -5.82 | -31.96 |
| Earnings per share, diluted | -2.38 | -5.82 | -31.96 |
| Weighted average shares, basic | 36,506,092 | 10,642,954 | 1,018,757 |
| Weighted average shares, diluted | 36,506,092 | 10,642,954 | 1,018,757 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding